Assuntos
National Heart, Lung, and Blood Institute (U.S.) , Pesquisa Biomédica/tendências , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/terapia , Saúde , Doenças Hematológicas/epidemiologia , Doenças Hematológicas/terapia , Humanos , National Heart, Lung, and Blood Institute (U.S.)/tendências , Doenças Respiratórias/epidemiologia , Doenças Respiratórias/terapia , Estados Unidos/epidemiologiaRESUMO
The National Heart, Lung, and Blood Institute (NHLBI) Clinical Proteomics Working Group was charged with identifying opportunities and challenges in clinical proteomics and using these as a basis for recommendations aimed at directly improving patient care. The group included representatives of clinical and translational research, proteomic technologies, laboratory medicine, bioinformatics, and 2 of the NHLBI Proteomics Centers, which form part of a program focused on innovative technology development. This report represents the results from a one-and-a-half-day meeting on May 8 and 9, 2003. For the purposes of this report, clinical proteomics is defined as the systematic, comprehensive, large-scale identification of protein patterns ("fingerprints") of disease and the application of this knowledge to improve patient care and public health through better assessment of disease susceptibility, prevention of disease, selection of therapy for the individual, and monitoring of treatment response.